|
Workshop
[postponed] Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
Speakers:
Organizers:
Rebecca Elliott, Weili Yan and Surinder Kaur (Genentech)
Date:
2020-05-12- 5/12/2020
Time:
8:45-11:50 Pacific Time
Registration fee:
(USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
(3)BioAgilytix Labs; Mercodia; MicroConstants
Registration: http://www.PBSS.org
Registration deadline:2020-09-16
(it will close sooner if the seating cap is reached)
About the Topic
Validated bioanalytical methods for the quantitative evaluation of large molecule drugs and biomarkers in a given biological matrix are critical for the successful conduct of nonclinical and clinical studies. These validated methods under regulated GxP environment provide critical data to support the safety and effectiveness of drugs and biologic products. Ligand binding assays (LBA) and emerging new technologies are widely used for regulated large molecule bioanalysis.
The workshop includes an introduction to regulated bioanalytical method development/validation and sample testing, focusing on new FDA guidance and future global harmonized guidance for large molecule bioanalysis. Applying general bioanalytical principles to emerging new technologies and/or new drug entities such as cell and gene therapy to meet health authorities’ compliance requirements will also be presented by industry recognized experts.
The following topics will be covered:
- Introduction: Fundamentals of large molecule bioanalysis- method development, regulated validation and sample testing
- 2018 FDA bioanalytical method validation guidance, changes from previous guidance, future global harmonized guidance
- Hybrid LBA/LC-MS bioanalytical method
- New technologies in large molecule bioanalysis
- Cross validation
- Life cycle management of bioanalytical method (critical reagents)
- Bioanalysis in gene and/or cell therapy
- Method transfer, validation, production from CRO perspective
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|